The new COX-2 inhibitor NSAID Prexige is now available in Australia, New Zealand and quite a few other countries around the world, but not the USA. The USA FDA has much more stringent pre-release data required after the Vioxx fiasco. Prexige has apparently passed all of the hurdles with respect to safety. However, its efficacy has only been tested in a European population and the FDA apparently won't let in on to the US market until it is tested on Americans, because - apparently - the European women aren't fat enough to be considered representative of the US population.
Maybe McDonald's does the same thing when they are testing their hamburgers.